In a move to protect children, Greece recently passed a stringent law that imposes jail time for individuals caught selling alcohol or tobacco to minors. This new legislation aims to safeguard the well-being of young people and curb underage substance abuse. The Greek government’s decision underscores a growing concern over the impact of alcohol and

BioVersys and Shionogi have joined forces in an exciting partnership aimed at advancing innovative treatments for infectious diseases. The collaboration focuses on the development of new ansamycin leads as part of BioVersys’ BV500 programme. This strategic alliance marks a significant step towards addressing unmet medical needs in the field of infectious diseases. The BV500 programme,

Five years ago, a sales representative was scrambling to contact a healthcare professional (HCP). However, they were faced with three different records, each presenting conflicting information. The leadership team was struggling to generate accurate global reports due to discrepancies in customer data. This challenge stemmed from the varied types of HCPs and their specialties across

Organ donation plays a vital role in saving lives around the world. However, in Central Asia, specifically Kazakhstan and other neighboring countries, organ transplantation faces significant challenges that lead to a heavy reliance on living donors over posthumous donations. In 2024, only a small fraction of families in Kazakhstan consented to donation after death, with

In the world of cancer treatment, advancements are always cause for celebration. Imagine the hope that lights up in the eyes of patients and their families when a new therapy shows promise. The recent buzz at the ASCO25 conference was all about Regeneron’s groundbreaking data on Libtayo (cemiplimab) in treating high-risk cutaneous squamous cell carcinoma

In the bustling landscape of medical advancements, a recent milestone has been achieved with the conditional approval of Zymeworks’ zanidatamab in China. This approval by China’s National Medical Products Administration (NMPA) marks a significant step forward in the treatment of individuals battling prior treated, unresectable or metastatic human epidermal growth factor receptor 2-positive (HER2+) biliary